Allergy Therapeutics
plc
("Allergy
Therapeutics" or the "Group")
Result of Annual General
Meeting
8
March 2024 Allergy Therapeutics plc
(AIM:AGY), the fully integrated specialty pharmaceutical group
specialising in allergy vaccines, announces that all resolutions
proposed at the 2023 Annual General Meeting ("AGM") held today were
duly passed by shareholders by way of poll vote.
Resolutions 1 to 11 (inclusive) were
proposed as ordinary resolutions and resolutions 12 to 14
(inclusive) were proposed as special resolutions. The results of
the proxy votes received ahead of the meeting are outlined in the
table below.
|
Resolution
|
For:
|
%age
|
Against:
|
%age
|
Total Votes
Cast
|
Withheld
|
|
1. Approval
of 2023 Accounts
|
4,454,427,655
|
100.00%
|
100,000
|
0.00%
|
4,454,529,660
|
2,005
|
|
2. Approval
of Directors'
Remuneration Report
|
4,440,353,568
|
99.68%
|
14,174,087
|
0.32%
|
4,454,529,660
|
2,005
|
|
3. To
re-elect Mary Tavener as a Director
|
4,454,239,121
|
99.99%
|
278,279
|
0.01%
|
4,454,529,660
|
12,260
|
|
4. To
re-elect Tunde Otulana as a Director
|
4,454,384,117
|
100.00%
|
133,283
|
0.00%
|
4,454,529,660
|
12,260
|
|
5. To
re-elect Manuel Llobet as a Director
|
4,454,284,117
|
99.99%
|
233,283
|
0.01%
|
4,454,529,660
|
12,260
|
|
6. To
re-elect Cheryl MacDiarmid as a Director
|
4,454,384,117
|
100.00%
|
133,283
|
0.00%
|
4,454,529,660
|
12,260
|
|
7. To
re-elect Peter Jensen O.B.E. as a Director
|
4,440,494,882
|
99.69%
|
14,015,154
|
0.31%
|
4,454,529,660
|
19,624
|
|
8. To
re-appoint BDO LLP as auditors of the Company
|
4,454,306,655
|
100.00%
|
221,000
|
0.00%
|
4,454,529,660
|
2,005
|
|
9. To
authorise the Directors to agree the Auditors
remuneration
|
4,454,415,654
|
100.00%
|
108,001
|
0.00%
|
4,454,529,660
|
6,005
|
|
10. To
authorise the Directors to allot the unissued share capital up to a
specific amount (s.551)
|
4,454,236,175
|
99.99%
|
291,480
|
0.01%
|
4,454,529,660
|
2,005
|
|
11.
Authority to issue warrants
|
4,440,359,504
|
99.68%
|
14,168,151
|
0.32%
|
4,454,529,660
|
2,005
|
|
12.
Special Resolution:
To authorise the Directors to allot equity securities for cash
without first being required to offer such shares to existing
shareholders for a period expiring at the conclusion of the next
annual general meeting of the Company or 31 December 2024,
whichever occurs first.
|
4,440,458,304
|
99.68%
|
14,069,351
|
0.32%
|
4,454,529,660
|
2,005
|
|
13.
Special Resolution: To
authorise the Directors to allot equity
securities
and/or sell treasury shares for cash without first
being
required to offer such securities to existing
shareholders
|
4,440,458,304
|
99.68%
|
14,069,351
|
0.32%
|
4,454,529,660
|
2,005
|
|
14.
Special Resolution: Disapplication of pre-emption
rights in
relation to the Warrants
|
4,440,428,445
|
99.68%
|
14,095,210
|
0.32%
|
4,454,529,660
|
6,005
|
- ENDS -
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0)1903 845 820
Panmure Gordon (Nominated Adviser and
Broker)
Emma Earl, Mark Rogers, Freddy
Crossley, Corporate Finance
Rupert Dearden, Corporate
Broking
+44 (0)20 7886 2500
ICR
Consilium
Mary-Jane Elliott / David Daley /
Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy
Therapeutics
Allergy
Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of
allergic disorders, including aluminium free immunotherapy vaccines
that have the potential to cure disease. The Group sells
proprietary and third-party products from its subsidiaries in nine
major European countries and via distribution agreements in an
additional ten countries. Its broad pipeline of products in
clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see
www.allergytherapeutics.com.